ATE454901T1 - Verfahren zur erhaltung zellimmuneantworten gegen proteinen - Google Patents
Verfahren zur erhaltung zellimmuneantworten gegen proteinenInfo
- Publication number
- ATE454901T1 ATE454901T1 AT00968937T AT00968937T ATE454901T1 AT E454901 T1 ATE454901 T1 AT E454901T1 AT 00968937 T AT00968937 T AT 00968937T AT 00968937 T AT00968937 T AT 00968937T AT E454901 T1 ATE454901 T1 AT E454901T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- immune responses
- cell immune
- maintaining cell
- vertebrate subject
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 2
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15929899P | 1999-10-13 | 1999-10-13 | |
PCT/US2000/028040 WO2001026681A2 (en) | 1999-10-13 | 2000-10-10 | Method of obtaining cellular immune responses from proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE454901T1 true ATE454901T1 (de) | 2010-01-15 |
Family
ID=22571953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00968937T ATE454901T1 (de) | 1999-10-13 | 2000-10-10 | Verfahren zur erhaltung zellimmuneantworten gegen proteinen |
Country Status (10)
Country | Link |
---|---|
US (2) | US6534064B1 (de) |
EP (1) | EP1221968B1 (de) |
JP (2) | JP2003511420A (de) |
AT (1) | ATE454901T1 (de) |
AU (1) | AU7877900A (de) |
CA (1) | CA2388676A1 (de) |
DE (1) | DE60043708D1 (de) |
ES (1) | ES2337017T3 (de) |
PT (1) | PT1221968E (de) |
WO (1) | WO2001026681A2 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141244B1 (en) * | 1992-03-02 | 2006-11-28 | Chiron Srl | Helicobacter pylori proteins useful for vaccines and diagnostics |
AU1463097A (en) * | 1996-01-04 | 1997-08-01 | Rican Limited | Helicobacter pylori bacterioferritin |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
GB9807721D0 (en) * | 1998-04-08 | 1998-06-10 | Chiron Spa | Antigen |
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
JP2003511420A (ja) * | 1999-10-13 | 2003-03-25 | カイロン コーポレイション | タンパク質から細胞性免疫応答を得る方法 |
ES2258108T3 (es) * | 2000-11-07 | 2006-08-16 | Immunovaccine Technologies Inc. | Vacunas con respuesta inmune mejorada y procedimientos de preparacion de las mismas. |
DE60239317D1 (de) * | 2001-01-12 | 2011-04-14 | Novartis Vaccines & Diagnostic | Nukleinsäure mukosale immunisierung |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
ITRM20010336A1 (it) * | 2001-06-13 | 2002-12-13 | Biostrands S R L | Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi |
US20040185057A1 (en) * | 2001-06-15 | 2004-09-23 | Kirkby Nikolai Soren | Therapeutical vaccination |
WO2003002065A2 (en) * | 2001-06-29 | 2003-01-09 | Chiron Corporation | Hcv e1e2 vaccine compositions |
AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
JP2005506322A (ja) * | 2001-08-31 | 2005-03-03 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Helicobacterpyloriワクチン接種 |
JP4516748B2 (ja) | 2001-09-14 | 2010-08-04 | サイトス バイオテクノロジー アーゲー | ウィルス様粒子中への免疫賦活物質のパッケージ化:調製法および使用法 |
EP1490099A4 (de) * | 2002-03-13 | 2006-02-08 | Kirin Brewery | Humane monoklonale antikörper gegen influenza m2 protein und verfahren zu seiner herstellung und verwendung |
US7056901B2 (en) | 2002-03-29 | 2006-06-06 | The Regents Of The University Of California | Microgel particles for the delivery of bioactive materials |
JP2004099584A (ja) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Hsvを用いた抗腫瘍剤 |
US8034378B2 (en) * | 2002-12-27 | 2011-10-11 | Novartis Vaccines And Diagnostics, Inc | Immunogenic compositions containing phospholipid |
JP2007524609A (ja) * | 2003-04-10 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | コンフォメーションに関する変種のプロファイリング、抗体組成物 |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
FR2859909B1 (fr) | 2003-09-22 | 2007-09-07 | Biomerieux Sa | Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation |
EP2963118B1 (de) * | 2005-06-01 | 2017-08-09 | California Institute of Technology | Verfahren zur gezielten genabgabe über virale vektoren |
CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
CA2626257A1 (en) * | 2005-10-17 | 2007-04-26 | Novartis Ag | Multiclade hiv vaccines |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
NZ573622A (en) | 2006-06-12 | 2011-12-22 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
KR101421312B1 (ko) * | 2006-07-21 | 2014-07-31 | 캘리포니아 인스티튜트 오브 테크놀로지 | 수지상 세포 백신접종을 위한 표적화된 유전자의 전달 |
CA2671873C (en) | 2006-12-12 | 2018-10-09 | Brian Stephen Sproat | Oligonucleotides containing high concentrations of guanine monomers |
JP5731198B2 (ja) | 2007-09-27 | 2015-06-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用 |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
EP3067048B1 (de) | 2007-12-07 | 2018-02-14 | GlaxoSmithKline Biologicals SA | Zusammensetzungen zur induzierung von immunreaktionen |
WO2009146523A1 (en) * | 2008-06-05 | 2009-12-10 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
CA2730760A1 (en) * | 2008-07-16 | 2010-01-21 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles containing bioactive peptides |
SI2456786T2 (sl) | 2009-07-24 | 2017-08-31 | Immune Design Corp. | Lentiviralni vektorji psevdo-tipizirani z glikoproteinom ovojnice virusa Sindbis |
EP2550362B1 (de) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
BR112014007927B1 (pt) | 2011-10-06 | 2021-04-13 | Immunovaccine Technologies Inc | Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
DK2831095T3 (en) | 2012-03-30 | 2019-02-18 | Immune Design Corp | LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN |
US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
US20130302366A1 (en) | 2012-05-09 | 2013-11-14 | Christopher Marshall | Conformationally Specific Viral Immunogens |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
RU2019110875A (ru) | 2016-09-13 | 2020-10-15 | Аллерган, Инк. | Небелковые композиции клостридиального токсина |
WO2018055535A2 (en) | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2750045A1 (de) * | 1977-11-09 | 1979-05-10 | Behringwerke Ag | Verfahren zur entfernung von detergentien aus virusantigensuspensionen |
US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
JPS62138500A (ja) * | 1985-12-11 | 1987-06-22 | Sumitomo Pharmaceut Co Ltd | ポリペプチドの製法 |
JPH01500999A (ja) * | 1986-10-20 | 1989-04-06 | チロン コーポレイション | Hsvの治療的処置に用いるワクチン |
JPH0751513B2 (ja) * | 1988-04-28 | 1995-06-05 | 国立予防衛生研究所長 | A型肝炎ワクチン |
CA2037151A1 (en) * | 1990-03-23 | 1991-09-24 | F. Hoffmann-La Roche Ag | Plasmodium sporozoite antigen |
JPH07505412A (ja) * | 1992-04-14 | 1995-06-15 | ブリティッシュ バイオテック ファーマシューティカルズリミテッド | Ctl応答の誘導 |
EP0678034B1 (de) * | 1993-01-11 | 1999-05-26 | Dana Farber Cancer Institute | Induktion der antworten zytotoxischer t-lymphozyten |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5709995A (en) * | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
US5851826A (en) * | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
ZA982763B (en) * | 1997-04-09 | 1998-10-05 | Akzo Nobel Nv | Vaccines |
EP0980257A1 (de) | 1997-05-01 | 2000-02-23 | Chiron Corporation | Verwendung von virusähnlichen partikeln als adjuvantien |
EP0913479A3 (de) * | 1997-10-27 | 2000-10-25 | Smithkline Beecham Corporation | Adenin Glycosylase |
EP1042001B1 (de) * | 1997-12-16 | 2002-04-03 | Chiron Corporation | Verwendung von mikropartikeln mit submikron öl/wasser emulsionen |
NZ528952A (en) * | 1998-06-24 | 2004-09-24 | Innogenetics N | Particles of HCV envelope proteins: use for vaccination |
JP2003511420A (ja) * | 1999-10-13 | 2003-03-25 | カイロン コーポレイション | タンパク質から細胞性免疫応答を得る方法 |
-
2000
- 2000-10-10 JP JP2001529742A patent/JP2003511420A/ja not_active Withdrawn
- 2000-10-10 AU AU78779/00A patent/AU7877900A/en not_active Abandoned
- 2000-10-10 WO PCT/US2000/028040 patent/WO2001026681A2/en active Application Filing
- 2000-10-10 DE DE60043708T patent/DE60043708D1/de not_active Expired - Lifetime
- 2000-10-10 US US09/686,345 patent/US6534064B1/en not_active Expired - Lifetime
- 2000-10-10 AT AT00968937T patent/ATE454901T1/de active
- 2000-10-10 ES ES00968937T patent/ES2337017T3/es not_active Expired - Lifetime
- 2000-10-10 CA CA002388676A patent/CA2388676A1/en not_active Abandoned
- 2000-10-10 PT PT00968937T patent/PT1221968E/pt unknown
- 2000-10-10 EP EP00968937A patent/EP1221968B1/de not_active Expired - Lifetime
-
2003
- 2003-01-08 US US10/340,034 patent/US7604802B2/en not_active Expired - Fee Related
-
2011
- 2011-03-22 JP JP2011063393A patent/JP2011116796A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ES2337017T3 (es) | 2010-04-20 |
WO2001026681A2 (en) | 2001-04-19 |
CA2388676A1 (en) | 2001-04-19 |
WO2001026681A3 (en) | 2002-01-31 |
DE60043708D1 (de) | 2010-03-04 |
US6534064B1 (en) | 2003-03-18 |
US20030104067A1 (en) | 2003-06-05 |
EP1221968B1 (de) | 2010-01-13 |
PT1221968E (pt) | 2010-04-16 |
US7604802B2 (en) | 2009-10-20 |
EP1221968A2 (de) | 2002-07-17 |
JP2003511420A (ja) | 2003-03-25 |
JP2011116796A (ja) | 2011-06-16 |
AU7877900A (en) | 2001-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE454901T1 (de) | Verfahren zur erhaltung zellimmuneantworten gegen proteinen | |
ATA1292000A (de) | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen | |
PL401469A1 (pl) | Pochodna azabicykliczna, sposób jej wytwarzania, jej zastosowanie w medycynie oraz zawierajaca pochodna kompozycja | |
AU2903999A (en) | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines | |
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
IL132468A0 (en) | A kit for inducing immune response against a tumor or a disease caused by an infection agent | |
EE05212B1 (et) | Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i | |
BG104828A (en) | Fap alpha-specific antibody with improved pruducibility | |
EP2325205A3 (de) | Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung | |
DK0757717T3 (da) | Papillomavirusvacciner | |
ATE236255T1 (de) | Impfstoff gegen den hepatitis e-virus und verfahren | |
DE69930630D1 (de) | B2microglobulin fusionsproteine und varianten mit hoher affinität | |
JP2003515569A5 (de) | ||
WO2002088328A8 (en) | Method for generating highly active human dendritic cells from monocytes | |
DE60331725D1 (de) | Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren | |
ATE344052T1 (de) | Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt. | |
EP1801123A3 (de) | Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung | |
ATE341339T1 (de) | Zusammensetzungen von rekombinanten papillomavirus vakzinen | |
ATE310750T1 (de) | Verotoxin b untereinheit zur immunisierunug | |
AU7546500A (en) | Designing immunogens | |
EP1131338A4 (de) | Methode für die herstellung von gereinigtem invasinprotein und seine anwendung | |
ATE385809T1 (de) | Saponin-zusammensetzungen und deren verwendung | |
WO2005035733A3 (en) | Modified whole cell, cell extract and omv-based vaccines | |
DE602004019141D1 (de) | Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide | |
AU2002221553A1 (en) | Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1221968 Country of ref document: EP |